vs
Side-by-side financial comparison of PagerDuty, Inc. (PD) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Stoke Therapeutics, Inc. is the larger business by last-quarter revenue ($158.6M vs $124.5M, roughly 1.3× PagerDuty, Inc.). PagerDuty, Inc. runs the higher net margin — 129.7% vs 71.2%, a 58.6% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 4.7%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $24.1M).
PagerDuty, Inc. is an American cloud computing company specializing in a SaaS incident management platform for IT operations departments.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
PD vs STOK — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $124.5M | $158.6M |
| Net Profit | $161.6M | $112.9M |
| Gross Margin | 85.3% | — |
| Operating Margin | 6.5% | 70.2% |
| Net Margin | 129.7% | 71.2% |
| Revenue YoY | 4.7% | 3661.1% |
| Net Profit YoY | 2827.7% | 528.0% |
| EPS (diluted) | $1.69 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $124.5M | — | ||
| Q3 25 | $123.4M | — | ||
| Q2 25 | $119.8M | — | ||
| Q1 25 | $121.4M | $158.6M | ||
| Q4 24 | $118.9M | $22.6M | ||
| Q3 24 | $115.9M | — | ||
| Q2 24 | $111.2M | — | ||
| Q1 24 | $111.1M | — |
| Q4 25 | $161.6M | — | ||
| Q3 25 | $9.6M | — | ||
| Q2 25 | $-7.2M | — | ||
| Q1 25 | $-8.8M | $112.9M | ||
| Q4 24 | $-5.9M | $-10.5M | ||
| Q3 24 | $-10.9M | — | ||
| Q2 24 | $-17.1M | — | ||
| Q1 24 | $-28.2M | — |
| Q4 25 | 85.3% | — | ||
| Q3 25 | 84.6% | — | ||
| Q2 25 | 84.0% | — | ||
| Q1 25 | 83.6% | — | ||
| Q4 24 | 83.0% | — | ||
| Q3 24 | 82.7% | — | ||
| Q2 24 | 82.6% | — | ||
| Q1 24 | 81.7% | — |
| Q4 25 | 6.5% | — | ||
| Q3 25 | 2.9% | — | ||
| Q2 25 | -8.6% | — | ||
| Q1 25 | -9.6% | 70.2% | ||
| Q4 24 | -8.7% | -60.4% | ||
| Q3 24 | -13.8% | — | ||
| Q2 24 | -19.5% | — | ||
| Q1 24 | -30.1% | — |
| Q4 25 | 129.7% | — | ||
| Q3 25 | 7.8% | — | ||
| Q2 25 | -6.0% | — | ||
| Q1 25 | -7.2% | 71.2% | ||
| Q4 24 | -5.0% | -46.4% | ||
| Q3 24 | -9.4% | — | ||
| Q2 24 | -15.4% | — | ||
| Q1 24 | -25.3% | — |
| Q4 25 | $1.69 | — | ||
| Q3 25 | $0.10 | — | ||
| Q2 25 | $-0.07 | — | ||
| Q1 25 | $-0.12 | $1.90 | ||
| Q4 24 | $-0.07 | $-0.15 | ||
| Q3 24 | $-0.14 | — | ||
| Q2 24 | $-0.26 | — | ||
| Q1 24 | $-0.34 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $547.8M | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $320.5M | $350.1M |
| Total Assets | $1.0B | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $547.8M | — | ||
| Q3 25 | $567.9M | — | ||
| Q2 25 | $597.1M | — | ||
| Q1 25 | $570.8M | $274.8M | ||
| Q4 24 | $542.2M | $128.0M | ||
| Q3 24 | $599.3M | — | ||
| Q2 24 | $592.8M | — | ||
| Q1 24 | $571.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $484.5M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $489.5M | — |
| Q4 25 | $320.5M | — | ||
| Q3 25 | $180.7M | — | ||
| Q2 25 | $145.7M | — | ||
| Q1 25 | $129.8M | $350.1M | ||
| Q4 24 | $111.6M | $229.0M | ||
| Q3 24 | $164.7M | — | ||
| Q2 24 | $174.0M | — | ||
| Q1 24 | $171.6M | — |
| Q4 25 | $1.0B | — | ||
| Q3 25 | $891.5M | — | ||
| Q2 25 | $926.8M | — | ||
| Q1 25 | $927.3M | $406.9M | ||
| Q4 24 | $866.8M | $271.6M | ||
| Q3 24 | $916.0M | — | ||
| Q2 24 | $924.0M | — | ||
| Q1 24 | $925.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.73× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.85× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $24.8M | $131.8M |
| Free Cash FlowOCF − Capex | $24.1M | $131.7M |
| FCF MarginFCF / Revenue | 19.3% | 83.0% |
| Capex IntensityCapex / Revenue | 0.6% | 0.1% |
| Cash ConversionOCF / Net Profit | 0.15× | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | $117.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.8M | — | ||
| Q3 25 | $34.0M | — | ||
| Q2 25 | $30.7M | — | ||
| Q1 25 | $31.4M | $131.8M | ||
| Q4 24 | $22.1M | $-23.2M | ||
| Q3 24 | $35.8M | — | ||
| Q2 24 | $28.6M | — | ||
| Q1 24 | $22.2M | — |
| Q4 25 | $24.1M | — | ||
| Q3 25 | $33.1M | — | ||
| Q2 25 | $30.2M | — | ||
| Q1 25 | $30.3M | $131.7M | ||
| Q4 24 | $21.5M | $-23.2M | ||
| Q3 24 | $35.1M | — | ||
| Q2 24 | $28.2M | — | ||
| Q1 24 | $21.2M | — |
| Q4 25 | 19.3% | — | ||
| Q3 25 | 26.8% | — | ||
| Q2 25 | 25.2% | — | ||
| Q1 25 | 24.9% | 83.0% | ||
| Q4 24 | 18.1% | -102.7% | ||
| Q3 24 | 30.3% | — | ||
| Q2 24 | 25.4% | — | ||
| Q1 24 | 19.1% | — |
| Q4 25 | 0.6% | — | ||
| Q3 25 | 0.7% | — | ||
| Q2 25 | 0.4% | — | ||
| Q1 25 | 0.9% | 0.1% | ||
| Q4 24 | 0.5% | 0.2% | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.9% | — |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 3.55× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.17× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PD
| US | $88.8M | 71% |
| Non Us | $35.7M | 29% |
STOK
Segment breakdown not available.
